Elanco Animal Health Incorporated ELAN will consolidate commercial operations for Elanco International and Elanco Europe into one organization under Ramiro Cabral, EVP & President Elanco International.
- The restructuring includes eliminating approximately 380 positions, including about 20% of Elanco's senior management.
- Elanco believes the move will help offset previously disclosed higher cost pressures and maintain its current path to 60% adjusted gross margin by 2023 and 31% adjusted EBITDA margin by 2024.
- Elanco expects to record a Q4 2021 pre-tax charge of $86 million - $94 million for severance costs.
- Reported Q4 net income is expected to reduce by $65 million - $71 million and EPS by approximately $0.13 to $0.15.
- The compensation and benefits savings in 2022 are anticipated to be approximately $60 million, and once fully implemented, are expected to provide annual savings of roughly $70 million.
- There is no change to the 2021 full-year guidance for revenue of $4.73 billion - $4.77 billion, adjusted EBITDA of $1.03 billion - $1.07 billion, and adjusted EPS of $0.97 - $1.03.
- Price Action: ELAN shares are down 1.62% at $29.70 on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in